Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GrayBug LLC

Delivering drugs to eye compartments, slowly

This article was originally published in Start Up

Executive Summary

Nearly 12 million intravitreal injections for ophthalmic disease were admistered to patients eyes in 2012, and the figure is a testament to the acceptability of the delivery method whose very concept once inspired gasps and doubts; still, meaningful improvements are almost certain to be welcome and reimbursed in the marketplace. GrayBug LLC is betting it can enhance the outcome of drugs injected into the eye by prolonging their release with a polymer-based delivery system that the firm expects to eventually be formulated as nanoparticles – the goal is to extend intervals between ocular medicine dosing to three months or longer, perhaps as long as six months, with reduced inflammatory effects.



Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts